iSpecimen Inc. (NASDAQ: ISPC) has 3,253,011 pre-funded warrants — contracts allowing the holder to convert to common stock at an exercise price of approximately $0.0001, meaning the conversion costs essentially nothing — outstanding against a public float of just 2,518,590 shares. That warrant block equals 129% of the entire tradeable float. Because pre-funded warrants are unissued until exercised, standard market-data terminals report the float at roughly 2.5 million shares. The effective supply, however, is 5,771,601 shares — 2.3 times what screens show.
The warrants are immediately exercisable. They carry no expiration date. The underlying shares are already registered under an effective S-1 registration statement — a filing that allows newly issued shares to trade freely the moment they are created, with no Rule 144 holding period. The only throttle is a 4.99% beneficial-ownership blocker, which the holder can raise to 9.99% on 61 days' notice. That meters the pace of conversion but not the total.
Where the warrants came from
The bulk — 2,849,923 warrants — were issued in a best-efforts registered offering that closed August 7, 2026. In a best-efforts deal, the placement agent (here, E.F. Hutton) agrees to try to sell the securities but does not guarantee the full amount will be raised. An additional 403,088 pre-funded warrants remain from a May 2026 private placement. In both deals, roughly three-quarters of the securities sold were taken as pre-funded warrants rather than common shares, a pattern that indicates buyers whose position sizes would breach the ownership cap.
A five-raise, thirteen-month cadence
ISPC has completed five separate capital raises since July 2025, at intervals of roughly 90 days. Each successive deal was priced at or below the prevailing market and structured with a dominant pre-funded warrant component. The August 2026 prospectus disclosed that proceeds plus existing cash fund approximately seven months of operations — a timeline that, based on the established cadence, points toward another raise as early as Q1 2027.
The company's shares outstanding grew 75.2% in a single quarter, from 1,437,157 on May 15 to 2,518,590 on August 14. On a split-adjusted twelve-month basis, the count rose 1,719%.
Two reverse splits, one pattern
iSpecimen executed a 1-for-20 reverse split in September 2024 and a 1-for-40 reverse split in April 2026, for cumulative compression of 1-for-800. The April 2026 split cured a Nasdaq minimum-bid-price deficiency. Within four months, the share count had already rebuilt from roughly 1.3 million to 2.5 million — the reset-and-refill cycle is demonstrably active.
Promotion spend alongside exercisable supply
Up to $2.0 million of the proceeds from the two most recent raises — $1.1 million from August 2026 and $900,000 from May 2026 — is contracted to a third-party firm for marketing and advertising. That spend is landing concurrently with a 3.25-million-share warrant block that can convert to free-trading stock at any time.
What is not present
The structure is free of several common dilution mechanisms. There are no variable-rate convertible notes — instruments whose conversion price drops as the stock falls. There is no equity line of credit (ELOC), no at-the-market (ATM) offering program, and total debt is zero. All 6,875 shares of Series C Convertible Preferred have been fully converted; none remain outstanding. Legacy warrants and options are struck at $2,012 to $6,400, thousands of times above current levels, and carry zero float impact.
The company retains 200 million authorized common shares against 2.5 million outstanding — a ratio of roughly 79-to-1 — plus 50 million authorized blank-check preferred shares that the Board can designate and issue without a shareholder vote.